Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial (Q30091)

From lgbtDB
Revision as of 21:45, 8 November 2024 by Superraptor (talk | contribs) (‎Added [en] label: Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial)
Jump to navigation Jump to search
No description defined
  • Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial.
Language Label Description Also known as
English
Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial
No description defined
  • Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial.

Statements

title
Addition of testosterone to endocrine care for transgender women: a dose-finding and feasibility trial. (English)
1 reference
stated in
PubMed
abstract
Transgender women who underwent gonadectomy have lower serum testosterone concentrations than cisgender women. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
1
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
There is uncertainty regarding the dosing and side effects of supplementation of testosterone in transgender women. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
2
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
This study aimed to assess the feasibility of dosing testosterone to the cisgender female physiological range in transgender women. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
3
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
In addition, we explored changes in cardiovascular parameters, virilizing side effects, and clinical symptoms. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
4
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
This is an open-label, single-arm feasibility study. (English)
source label
DESIGN (English)
subsection NLM category
methods section
series ordinal
5
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
Participants initially went through a dose-titration phase with 2-week intervals of 0.07-0.09-0.13 mL (277-318-403 μg bioavailable testosterone) testosterone 2% gel to establish a dose leading to serum testosterone concentrations between 1.5 and 2.5 nmol/L. (English)
source label
DESIGN (English)
subsection NLM category
methods section
series ordinal
6
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
This dose was then continued for 8 weeks. (English)
source label
DESIGN (English)
subsection NLM category
methods section
series ordinal
7
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
Participants applied daily transdermal testosterone 2% gel (Tostran®) at the prescribed dosage. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
8
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
Testosterone was measured every 2-4 weeks. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
9
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
Laboratory analyses, side effects, and clinical symptoms were evaluated. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
10
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
In total, 12 participants were included. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
11
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
Most participants required a dose of 0.07 mL (277 μg bioavailable testosterone) or 0.09 mL (318 μg bioavailable testosterone) to reach serum testosterone concentrations of 1.5-2.5 nmol/L. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
12
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
Continuing this dose, testosterone concentrations remained stable throughout the study. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
13
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
Changes in clinical outcomes were in the desired direction, and side effects were mild. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
14
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
The use of testosterone supplementation in transgender women seems feasible and safe in the short term. (English)
source label
CONCLUSIONS (English)
subsection NLM category
conclusion section
series ordinal
15
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
Although dosing requires personalized titration, stable testosterone levels can be established. (English)
source label
CONCLUSIONS (English)
subsection NLM category
conclusion section
series ordinal
16
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
A blinded, placebo-controlled, randomized clinical trial is needed to study the clinical benefit. (English)
source label
CONCLUSIONS (English)
subsection NLM category
conclusion section
series ordinal
17
copyright statement
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. (English)
publisher
Oxford University Press
on behalf of
European Society of Endocrinology
date copyrighted
2024
rights holder
Noor C. Gieles
Maurice A. G. M. Kroon
Stephanie Both
Annemieke C. Heijboer
Baudewijntje Kreukels
Martin den Heijer
1 reference
stated in
PubMed
date published
30 August 2024
1 reference
stated in
PubMed
date issued
30 August 2024
1 reference
stated in
PubMed
author
volume
191
1 reference
stated in
PubMed
issue
3
1 reference
stated in
PubMed
page(s)
279-287
1 reference
stated in
PubMed
page start
279
1 reference
stated in
PubMed
page end
287
1 reference
stated in
PubMed
date of article
unknown value
1 reference
stated in
PubMed
conflict-of-interest statement
Conflict of interest: None declared. (English)
series ordinal
1
1 reference
stated in
PubMed
 
Retrieved from "https://lgbtdb.wikibase.cloud/w/index.php?title=Item:Q30091&oldid=183237"